GlassScriptPhysician profile
Julius H Simon
NPI 1952395006
$2,300.72
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $309 · 2020: $118 · 2021: $137 · 2022: $726 · 2023: $523 · 2024: $488.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,011.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,011.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $427.40 | 2019-2024 | Gardasil 9, Vaxneuvance, Vaxelis |
| Ironshore Pharmaceuticals INC. | $407.36 | 2019-2024 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $264.56 | 2022-2024 | Qelbree, Qelbree |
| Corium, LLC | $248.13 | 2022-2024 | Azstarys |
| Glaxosmithkline, LLC. | $178.28 | 2019-2024 | Bexsero, Pediarix, Rotarix |
| Sanofi Pasteur INC. | $132.99 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $100.37 | 2019-2022 | |
| Seqirus USA INC | $99.08 | 2022-2024 | Flucelvax |
| Pfizer INC. | $87.77 | 2019-2024 | |
| Tris Pharma INC | $50.40 | 2020 | |
| Alexion Pharmaceuticals, INC. | $50.13 | 2019 | |
| Sobi, INC | $40.91 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $37.82 | 2019-2020 | |
| Ucb, INC. | $33.66 | 2023 | Nayzilam |
| Kaleo, INC. | $25.85 | 2020-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $22.37 | 2019 | |
| Shire North American Group INC | $19.03 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $16.19 | 2024 | Kristalose |
| Genentech USA, INC. | $15.82 | 2019 | |
| Novo Nordisk INC | $15.25 | 2020 | |
| Qol Medical, LLC | $13.78 | 2023 | Sucraid |
| Ultragenyx Pharmaceutical INC. | $13.57 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julius Simon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.